Do analysts recommend GMTX or DBVT?

DBV Technologies has a consensus target price of $48.50, suggesting a potential upside of 261.94%. Given DBV Technologies' stronger consensus rating and higher probable upside, analysts plainly believe DBV Technologies is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 DBV Technologies 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71

Does the media refer more to IDYA or DBVT?

In the previous week, IDEAYA Biosciences had 3 more articles in the media than DBV Technologies. MarketBeat recorded 10 mentions for IDEAYA Biosciences and 7 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.14 beat IDEAYA Biosciences' score of 0.73 indicating that DBV Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer DBVT or RGC?

DBV Technologies currently has a consensus price target of $48.50, indicating a potential upside of 261.94%. Given DBV Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe DBV Technologies is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DBV Technologies 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, DBVT or RGC?

Regencell Bioscience has lower revenue, but higher earnings than DBV Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DBV Technologies $5.64M 140.70 -$146.95M -$3.51 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Do analysts recommend DBVT or MOR?

DBV Technologies presently has a consensus target price of $48.50, suggesting a potential upside of 261.94%. Given DBV Technologies' stronger consensus rating and higher probable upside, equities analysts clearly believe DBV Technologies is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DBV Technologies 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is DBVT or MOR more profitable?

MorphoSys has a net margin of -226.79% compared to DBV Technologies' net margin of -3,506.53%. DBV Technologies' return on equity of -119.33% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets DBV Technologies -3,506.53% -119.33% -84.43% MorphoSys -226.79% -694.31% -22.55%

Does the media refer more to MBX or DBVT?

In the previous week, MBX Biosciences had 6 more articles in the media than DBV Technologies. MarketBeat recorded 13 mentions for MBX Biosciences and 7 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.14 beat MBX Biosciences' score of 0.85 indicating that DBV Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

DBV Technologies (DBVT) Competitors

$13.40 -0.10 (-0.74%)

As of 12:30 PM Eastern

Compare

DBVT vs. GMTX, IDYA, RGC, MOR, and MBX

Should you buy DBV Technologies stock or one of its competitors? MarketBeat compares DBV Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DBV Technologies include Gemini Therapeutics (GMTX), IDEAYA Biosciences (IDYA), Regencell Bioscience (RGC), MorphoSys (MOR), and MBX Biosciences (MBX).

How does DBV Technologies compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and DBV Technologies (NASDAQ:DBVT) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

DBV Technologies has a consensus target price of $48.50, suggesting a potential upside of 261.94%. Given DBV Technologies' stronger consensus rating and higher probable upside, analysts plainly believe DBV Technologies is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, DBV Technologies had 7 more articles in the media than Gemini Therapeutics. MarketBeat recorded 7 mentions for DBV Technologies and 0 mentions for Gemini Therapeutics. DBV Technologies' average media sentiment score of 1.14 beat Gemini Therapeutics' score of 0.00 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
DBV Technologies	Positive

Gemini Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. Gemini Therapeutics' return on equity of -38.78% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
DBV Technologies	-3,506.53%	-119.33%	-84.43%

Gemini Therapeutics has higher earnings, but lower revenue than DBV Technologies. Gemini Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
DBV Technologies	$5.64M	140.70	-$146.95M	-$3.51	N/A

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 1.1% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Gemini Therapeutics has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.93, suggesting that its stock price is 193% less volatile than the broader market.

Summary

Gemini Therapeutics and DBV Technologies tied by winning 8 of the 16 factors compared between the two stocks.

How does DBV Technologies compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and DBV Technologies (NASDAQ:DBVT) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

IDEAYA Biosciences currently has a consensus target price of $50.25, suggesting a potential upside of 42.33%. DBV Technologies has a consensus target price of $48.50, suggesting a potential upside of 261.94%. Given DBV Technologies' higher possible upside, analysts plainly believe DBV Technologies is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, IDEAYA Biosciences had 3 more articles in the media than DBV Technologies. MarketBeat recorded 10 mentions for IDEAYA Biosciences and 7 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.14 beat IDEAYA Biosciences' score of 0.73 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IDEAYA Biosciences has higher revenue and earnings than DBV Technologies. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$225.27M	13.77	-$113.70M	-$1.60	N/A
DBV Technologies	$5.64M	140.70	-$146.95M	-$3.51	N/A

IDEAYA Biosciences has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. IDEAYA Biosciences' return on equity of -14.24% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
DBV Technologies	-3,506.53%	-119.33%	-84.43%

IDEAYA Biosciences has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.93, suggesting that its share price is 193% less volatile than the broader market.

98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by insiders. Comparatively, 1.1% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

IDEAYA Biosciences beats DBV Technologies on 12 of the 17 factors compared between the two stocks.

How does DBV Technologies compare to Regencell Bioscience?

DBV Technologies (NASDAQ:DBVT) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

DBV Technologies currently has a consensus price target of $48.50, indicating a potential upside of 261.94%. Given DBV Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe DBV Technologies is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

DBV Technologies has a beta of -0.93, indicating that its share price is 193% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.84, indicating that its share price is 84% more volatile than the broader market.

Regencell Bioscience has lower revenue, but higher earnings than DBV Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	140.70	-$146.95M	-$3.51	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

In the previous week, DBV Technologies had 7 more articles in the media than Regencell Bioscience. MarketBeat recorded 7 mentions for DBV Technologies and 0 mentions for Regencell Bioscience. DBV Technologies' average media sentiment score of 1.14 beat Regencell Bioscience's score of 0.00 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
DBV Technologies	Positive
Regencell Bioscience	Neutral

Regencell Bioscience has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. Regencell Bioscience's return on equity of 0.00% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
Regencell Bioscience	N/A	N/A	N/A

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are owned by institutional investors. 1.1% of DBV Technologies shares are owned by insiders. Comparatively, 2.0% of Regencell Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

DBV Technologies beats Regencell Bioscience on 8 of the 14 factors compared between the two stocks.

How does DBV Technologies compare to MorphoSys?

DBV Technologies (NASDAQ:DBVT) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

DBV Technologies has a beta of -0.93, suggesting that its share price is 193% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

In the previous week, DBV Technologies had 7 more articles in the media than MorphoSys. MarketBeat recorded 7 mentions for DBV Technologies and 0 mentions for MorphoSys. DBV Technologies' average media sentiment score of 1.14 beat MorphoSys' score of 0.00 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
DBV Technologies	Positive
MorphoSys	Neutral

DBV Technologies has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	140.70	-$146.95M	-$3.51	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

MorphoSys has a net margin of -226.79% compared to DBV Technologies' net margin of -3,506.53%. DBV Technologies' return on equity of -119.33% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
MorphoSys	-226.79%	-694.31%	-22.55%

DBV Technologies presently has a consensus target price of $48.50, suggesting a potential upside of 261.94%. Given DBV Technologies' stronger consensus rating and higher probable upside, equities analysts clearly believe DBV Technologies is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 1.1% of DBV Technologies shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

DBV Technologies beats MorphoSys on 12 of the 17 factors compared between the two stocks.

How does DBV Technologies compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and DBV Technologies (NASDAQ:DBVT) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

MBX Biosciences has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.93, indicating that its stock price is 193% less volatile than the broader market.

MBX Biosciences has higher earnings, but lower revenue than DBV Technologies. MBX Biosciences is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
DBV Technologies	$5.64M	140.70	-$146.95M	-$3.51	N/A

MBX Biosciences has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. MBX Biosciences' return on equity of -24.52% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
DBV Technologies	-3,506.53%	-119.33%	-84.43%

71.7% of DBV Technologies shares are owned by institutional investors. 31.1% of MBX Biosciences shares are owned by insiders. Comparatively, 1.1% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MBX Biosciences presently has a consensus price target of $71.13, suggesting a potential upside of 8.35%. DBV Technologies has a consensus price target of $48.50, suggesting a potential upside of 261.94%. Given DBV Technologies' higher probable upside, analysts clearly believe DBV Technologies is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, MBX Biosciences had 6 more articles in the media than DBV Technologies. MarketBeat recorded 13 mentions for MBX Biosciences and 7 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.14 beat MBX Biosciences' score of 0.85 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MBX Biosciences beats DBV Technologies on 10 of the 15 factors compared between the two stocks.

Get DBV Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DBVT vs. The Competition

Export

Metric	DBV Technologies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$796.21M	$3.52B	$6.80B	$12.66B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-3.83	7.38	282.16	25.05
Price / Sales	140.70	1,220.59	576.18	79.91
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	3.19	16.79	10.96	6.18
Net Income	-$146.95M	-$12.56M	$3.49B	$347.61M
7 Day Performance	-3.60%	-0.84%	0.45%	0.71%
1 Month Performance	-15.30%	-7.59%	-4.26%	-3.75%
1 Year Performance	48.89%	49.20%	63.09%	20.17%

DBV Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DBVT DBV Technologies	3.2843 of 5 stars	$13.40 -0.7%	$48.50 +261.9%	+50.0%	$796.21M	$5.64M	N/A	80	Positive News
GMTX Gemini Therapeutics	N/A	$74.12 -2.3%	N/A	+30.6%	$3.21B	N/A	N/A	30	High Trading Volume
IDYA IDEAYA Biosciences	3.7485 of 5 stars	$35.83 -2.6%	$50.25 +40.2%	+46.3%	$3.15B	$225.27M	N/A	80	News Coverage Upcoming Earnings Gap Up
RGC Regencell Bioscience	0.1022 of 5 stars	$6.03 +3.4%	N/A	-52.4%	$2.97B	N/A	N/A	10
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DBVT) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DBV Technologies (DBVT) Competitors

DBVT vs. GMTX, IDYA, RGC, MOR, and MBX

How does DBV Technologies compare to Gemini Therapeutics?

Summary

How does DBV Technologies compare to IDEAYA Biosciences?

Summary

How does DBV Technologies compare to Regencell Bioscience?

Summary

How does DBV Technologies compare to MorphoSys?

Summary

How does DBV Technologies compare to MBX Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT vs. The Competition

DBV Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DBV Technologies (DBVT) Competitors

DBVT vs. GMTX, IDYA, RGC, MOR, and MBX

How does DBV Technologies compare to Gemini Therapeutics?

Do analysts recommend GMTX or DBVT?

Does the media favor GMTX or DBVT?

Is GMTX or DBVT more profitable?

Which has better valuation and earnings, GMTX or DBVT?

Do insiders and institutionals hold more shares of GMTX or DBVT?

Which has more volatility & risk, GMTX or DBVT?

Summary

How does DBV Technologies compare to IDEAYA Biosciences?

Do analysts prefer IDYA or DBVT?

Does the media refer more to IDYA or DBVT?

Which has preferable valuation & earnings, IDYA or DBVT?

Is IDYA or DBVT more profitable?

Which has more risk & volatility, IDYA or DBVT?

Do institutionals and insiders hold more shares of IDYA or DBVT?

Summary

How does DBV Technologies compare to Regencell Bioscience?

Do analysts prefer DBVT or RGC?

Which has more volatility and risk, DBVT or RGC?

Which has stronger valuation & earnings, DBVT or RGC?

Does the media favor DBVT or RGC?

Is DBVT or RGC more profitable?

Do insiders and institutionals believe in DBVT or RGC?

Summary

How does DBV Technologies compare to MorphoSys?

Which has more volatility and risk, DBVT or MOR?

Does the media prefer DBVT or MOR?

Which has stronger earnings & valuation, DBVT or MOR?

Is DBVT or MOR more profitable?

Do analysts recommend DBVT or MOR?

Do institutionals & insiders hold more shares of DBVT or MOR?

Summary

How does DBV Technologies compare to MBX Biosciences?

Which has more volatility & risk, MBX or DBVT?

Which has stronger earnings & valuation, MBX or DBVT?

Is MBX or DBVT more profitable?

Do institutionals and insiders hold more shares of MBX or DBVT?

Do analysts recommend MBX or DBVT?

Does the media refer more to MBX or DBVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT vs. The Competition

DBV Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools